Episode Details
Back to Episodes
SF Healthcare Week: Recursion's new CEO Najat Khan shares her vision for the company and for AI in biotech
Published 8 months ago
Description
Najat Khan describes the impact Recursion's work is having, such the surprising PoC of using MEK1/2 inhibition as a target for treating Familial Adenomatous Polyposis (PAP). Plus, she discusses other programs and large-pharma partnerships, and using new tools such as Boltz-2.